Document is current

Any future updates will be listed below

Überzeugende Phase-III-Daten zu Bimekizumab bei axialer Spondylarthritis

Crossref DOI link: https://doi.org/10.1007/s15002-022-3610-6

Published Online: 2022-08-17

Published Print: 2022-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark